As an element of Nautilus' overall reagent development and sourcing strategy, the partnership aims to accelerate research and development, and provide customers with access to Abcam's antibody development technology and expertise
Seattle and Cambridge, England (ots/PRNewswire) - Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or "Nautilus"), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, and Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life sciences research tools, today announced a ...
mehr